<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="22">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464631</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-HCV-001</org_study_id>
    <nct_id>NCT02464631</nct_id>
  </id_info>
  <brief_title>To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis</brief_title>
  <official_title>To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis&quot; - A Randomized Open- Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <authority>India: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective randomized trial, A Minimum of 300 consecutive patients of decompensated
      HCV (Hepatitis C Virus) related cirrhosis, presenting to the Institute of Liver and Biliary
      Sciences hospital will be included and those patients meeting the entry criteria received
      treatment with 400 mg of Sofosbuvir, administered orally once daily, and Ribavirin
      administered orally twice daily, with doses determined according to body weight(600 mg daily
      in patients with a body weight of ≤60 kg,800 mg daily in patients weighing &gt;60 and ≤80 kg,
      and1000 mg daily in patients with a body weight of &gt;80 kg). Based on the treatment duration,
      patients would be randomized in either of the 3 treatment groups -

        -  Group 1 - Sofosbuvir + Ribavirin x 24 weeks

        -  Group 2 - Sofosbuvir + Ribavirin x 36 weeks

        -  Group 3 - Sofosbuvir + Ribavirin x 48 weeks
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Primary efficacy end point is SVR 24 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoint is any AE (Adverse Event) leading to permanent discontinuation of study drugs.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at 6 months post therapy in all the 3 groups.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the liver function as determined by CTP (Child-Turcotte-Pugh score), MELD (Model for End Stage liver Disease)more than 2 points at 6 months and 1 year.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new cases of Hepatocellular Carcinoma at end of therapy and at 6 months post therapy in all the 3 groups.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in HVPG &gt;20% to baseline after 1 year in all the 3 groups.</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 4 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVR 12 defined as HCV RNA &lt;LLOQ (lower limit of quantification)</measure>
    <time_frame>36 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>HCV Related Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Sofosbuvir + Ribavirin 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sofosbuvir + Ribavirin x 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir + Ribavirin 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir + Ribavirin x 36 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sofosbuvir + Ribavirin 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sofosbuvir + Ribavirin x 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir + Ribavirin 1</intervention_name>
    <arm_group_label>Sofosbuvir + Ribavirin 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir + Ribavirin 2</intervention_name>
    <arm_group_label>Sofosbuvir + Ribavirin 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir + Ribavirin 3</intervention_name>
    <arm_group_label>Sofosbuvir + Ribavirin 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female ≥ 18 yrs

          -  Baseline HCV RNA &gt; 1000 IU/ml

          -  Cirrhosis with current or prior decompensation

          -  HCV (Hepatitis C Infection) Genotype 3

          -  Treatment naïve or treatment experienced

        Exclusion Criteria:

          -  HIV or HBV (Hepatitis B Virus) co-infection

          -  Recent Variceal bleed

          -  Pregnancy

          -  Haemolytic anaemia

          -  Platelet counts &lt;20,000/ml

          -  Advanced HCC (Hepatocellular Carcinoma)

          -  Renal dysfunction, GFR (glomerular filtration rate) &lt; 30 ml/min

          -  Haemoglobin &lt; 10 g/dl

          -  MELD (Model for End Stage Liver Disease) &gt;25, CTP (Child-Turcotte-Pugh score) &gt;12

          -  Post organ transplant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ankur Jindal, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver and Biliary Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ankur Jindal, DM</last_name>
    <phone>+91-46300000</phone>
    <email>ankur.jindal3@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver and Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <lastchanged_date>June 26, 2015</lastchanged_date>
  <firstreceived_date>May 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
